|
Baseline characteristics of the four study groups. |
||||
| Variable |
Infection/No treatment (n = 100) |
No infection/No treatment (n = 100) |
Infection/treatment (n = 100) |
No infection/Treatment (n = 100) |
|
|
||||
| Age (years) |
||||
| Mean (SD) |
9.5 (2.0) |
9.3 (1.8) |
9.2 (1.6) |
9.4 (1.8) |
| Sex |
||||
| Male/Female |
55/45 |
47/43 |
50/50 |
54/46 |
| Socioeconomic level |
||||
| Mean (SD) |
2.6 (1.1) |
2.0 (0.9) |
2.2 (0.9) |
1.9 (0/8) |
| Body mass index (kg/m2) |
||||
| Mean (SD) |
15.8 (1.8) |
15.9 (2.5) |
15.6 (1.5) |
16.1 (2.4) |
| Crowding (persons/room) |
||||
| Mean (SD) |
2.7 (1.2) |
2.4 (1.2) |
2.8 (1.1) |
2.4 (1.1) |
| Geohelminth prevalence (%) |
||||
| Any |
100 |
0 |
100 |
0 |
| A. lumbricoides |
75 |
0 |
73 |
0 |
| T. trichiura |
76 |
0 |
80 |
0 |
| Hookworm |
19 |
0 |
15 |
0 |
| S. stercoralis |
3 |
0 |
3 |
0 |
| Intensity, GM (range) epg |
||||
| A. lumbricoides |
5,658 (70–227,500) |
0 |
6,512 (70–182,700) |
0 |
| T. trichiura |
602 (70–40,250) |
0 |
583 (70–13,720) |
0 |
| Number of albendazole treatments |
||||
| 0 |
98% |
97% |
0% |
0% |
| 1–3 |
2% |
2% |
4% |
0% |
| 4–6 |
0% |
0% |
3% |
8% |
| 7 |
0% |
1% |
93% |
92% |
|
GM – geometric mean. SD – standard deviation. Epg – eggs per gramme of stool. Anthelmintic treatments were with single doses of 400 mg of albendazole. | ||||
Cooper et al. BMC Immunology 2008 9:33 doi:10.1186/1471-2172-9-33 |
||||